199 related articles for article (PubMed ID: 28917533)
1. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated polymeric carriers for liver targeting of sorafenib.
Craparo EF; Sardo C; Serio R; Zizzo MG; Bondì ML; Giammona G; Cavallaro G
Int J Pharm; 2014 May; 466(1-2):172-80. PubMed ID: 24607205
[TBL] [Abstract][Full Text] [Related]
3. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
4. PHEA-graft-polybutylmethacrylate copolymer microparticles for delivery of hydrophobic drugs.
Licciardi M; Di Stefano M; Craparo EF; Amato G; Fontana G; Cavallaro G; Giammona G
Int J Pharm; 2012 Aug; 433(1-2):16-24. PubMed ID: 22575755
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
[TBL] [Abstract][Full Text] [Related]
6. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Khan MA; Ali S; Venkatraman SS; Sohail MF; Ovais M; Raza A
Int J Pharm; 2018 May; 542(1-2):196-204. PubMed ID: 29551745
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
Zhao M; Lee SH; Song JG; Kim HY; Han HK
Int J Pharm; 2018 Jun; 544(1):14-20. PubMed ID: 29655795
[TBL] [Abstract][Full Text] [Related]
9. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
11. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
[TBL] [Abstract][Full Text] [Related]
12. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
Cai M; Li B; Lin L; Huang J; An Y; Huang W; Zhou Z; Wang Y; Shuai X; Zhu K
Biomater Sci; 2020 Jun; 8(12):3485-3499. PubMed ID: 32432234
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
[TBL] [Abstract][Full Text] [Related]
14. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
15. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
16. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Wang Y; Molin DG; Sevrin C; Grandfils C; van den Akker NM; Gagliardi M; Knetsch ML; Delhaas T; Koole LH
Int J Pharm; 2016 Apr; 503(1-2):150-62. PubMed ID: 26965198
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
19. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
[TBL] [Abstract][Full Text] [Related]
20. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
